BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 136 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $134,000 | -60.8% | 10,677 | -49.2% | 0.02% | -40.5% |
| Q1 2022 | $342,000 | -82.1% | 21,035 | -91.8% | 0.04% | -76.1% |
| Q4 2020 | $1,908,000 | +418.5% | 256,210 | +231.4% | 0.16% | +307.9% |
| Q2 2020 | $368,000 | +332.9% | 77,301 | +212.9% | 0.04% | +1166.7% |
| Q4 2019 | $85,000 | +3.7% | 24,704 | -14.7% | 0.00% | -25.0% |
| Q3 2019 | $82,000 | -57.3% | 28,949 | +21.6% | 0.00% | -60.0% |
| Q4 2018 | $192,000 | -55.1% | 23,800 | -68.2% | 0.01% | +11.1% |
| Q2 2018 | $428,000 | +46.1% | 74,800 | -27.9% | 0.01% | -35.7% |
| Q1 2016 | $293,000 | +35.0% | 103,800 | +443.5% | 0.01% | -12.5% |
| Q3 2015 | $217,000 | -15.9% | 19,100 | +10.4% | 0.02% | -59.0% |
| Q2 2015 | $258,000 | +113.2% | 17,300 | +50.4% | 0.04% | +550.0% |
| Q1 2014 | $121,000 | – | 11,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |